Browse by Medical Category
Research at Mass General
A research team at Massachusetts General Hospital is hoping to create new treatments for shigellosis, a potentially fatal digestive disorder, by factoring in genetic changes that occur in Shigella bacteria during the journey through the human digestive system.
Christina Faherty, PhD
From a human perspective, there is a lot to dislike about Shigella.
The more you learn about these infection-causing microbes, the easier it is to picture them as the dastardly, mustache-twirling villains of the microbial world.
Let’s take a quick look at Shigella’s rap sheet.
Shigella is a group of pathogenic bacteria that has evolved over millions of years specifically to infect humans. It is primarily transmitted through contaminated food or water, but it can also be transmitted through surface contact.
A shigellosis infection can cause a bad case of diarrhea, fever and stomach cramps that lasts from five to seven days. Shigella causes about 500,000 cases of diarrhea in the United States annually. Fortunately, most cases resolve without causing lasting damage.
Worldwide, Shigella is a much bigger problem. It is estimated to cause up to 165 million cases of disease and 600,000 deaths each year, primarily in children under the age of five in developing nations. To add to the challenge, there are new, antibiotic-resistant strains of Shigella emerging that are much more difficult to treat.
Christina Faherty, PhD, a researcher at the Mucosal Immunology and Biology Research Center at Massachusetts General Hospital for Children, is developing two new strategies for treating Shigella that could finally overcome 50 years of failed treatment efforts.
Faherty’s research team has demonstrated that Shigella undergoes a series of changes as it travels through the human digestive system, primarily as a result of exposure to bile in the small intestine.
The changes, which are driven by genes within the bacteria, help to protect it during its journey through the stomach and small intestine, and prepare it to attack the cells of the intestinal lining once it arrives in the colon.
By exposing Shigella to bile salts in the lab, Faherty has identified several strategies the bacteria employs for self-preservation, including the formation of a biofilm, which provides a protective niche for bacterial cells, and the activation of a molecular efflux pump to remove bile that makes it into the bacterial cell.
This image from an electron microscope shows the biofilm that Shigella use to protect themselves from bile salts.
Researchers have demonstrated similar bile-specific responses in other types of infectious bacteria, including Vibrio and pathogenic Escherichia coli.
From a scientific perspective, Faherty can’t help feeling a grudging admiration for these strategies, even as she works to defeat them.
“To me it seems like these pathogens have their own little brain, and they know how to manipulate the host and cause infection. It’s really interesting what they’re doing, but I want to stop them from doing it.”
The changes that Shigella undergo during their journey means that the microbes that launch their attack in the colon look a lot different from the Shigella strains that have been cultured in the laboratory. One reason for the lack of success in developing a vaccine could be that the immune system of a vaccinated individual does not recognize the bacteria following gastrointestinal transit.
Faherty hopes to create a more effective vaccine by adjusting the lab culture process to better replicate the conditions the bacteria are exposed to in the digestive system, which could hopefully prime the body to respond to the bacteria at the point of attack.
With the help of a grant from the Bill & Melinda Gates Foundation, Faherty is also collaborating with researchers at MIT to develop new bacteriophages—custom-made viruses that could be designed to infect and kill Shigella--in the intestines without harming beneficial bacteria.
Vaccines and bacteriophages could be crucial to treating shigellosis in the future, given the skyrocketing rates of antibiotic resistance. “It’s a huge problem,” Faherty says. “We are running out of antibiotics at this point.”
Faherty’s research has demonstrated that many of the mechanisms Shigella employs to resist bile are also used to resist antibiotics. “The sheer fact that they are exposed to bile on their way to the colon enhances their ability to resist certain antibiotics.”
Faherty explains that the same molecular pump Shigella uses to identify and remove bile from the bacterial cell is also used to identify and remove antibiotics.
“If you are going to design a new antibiotic, it is important to determine if the new candidate will be affected by the same mechanisms. Otherwise, resistance to this new antibiotic will quickly develop.”
“This is going to be a constant battle,” Faherty acknowledges. “Infectious bacteria have been around for millions of years, and they know what they’re doing, so we’re going to have to constantly stay ahead of them.”
Did you know that Massachusetts General Hospital is home to the largest hospital-based research program in the United States? Research at Mass General takes place in over 30 departments, institutes and centers throughout the hospital, and is powered by a community of 8,500+ people.
Our research programs help to further our understanding of the causes and progression of disease, develop new ways to diagnose and treat patients, and identify new strategies to increase the accessibility and affordability of healthcare—both here at Mass General and across the globe.
The Mass General Research Institute was launched in 2015 to promote, support and guide the hospital’s existing research enterprise. To learn more, please connect with us on Facebook and Twitter, and check out our research blog.
Back to Top